Ab­b­Vie, in­dus­try group push for in­ter­na­tion­al com­pro­mise on when tri­al in­ves­ti­ga­tors should re­ceive un­blind­ed da­ta

Ab­b­Vie and in­dus­try group Tran­sCel­er­ate Bio­phar­ma are tak­ing is­sue with the FDA’s at­tempt to change when cer­tain IND safe­ty re­ports should be un­blind­ed.

Back in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER